SV Life Sciences said it raised $274 million of the $400 million it hopes to put into its 6th fund for investing in healthcare companies.
The Boston-based venture capital shop said in a regulatory filing that 24 unnamed investors participated in the round, which began in May 2015.
SV Life Sciences, which has some $1.9 billion under management, invests in medical device, biotech and healthcare services companies.
Its medtech portfolio includes AcuFocus, CardioFocus, CardioKinetix, Direct Flow Medical, Insulet (NSDQ:PODD), ReShape Medical, TransEnterix (NYSE:TRXC) and Ximedica.
The VC firm raised a $523 million fund back in 2010.
